Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie and Genmab are conducting a Phase 3 clinical study to evaluate the safety and efficacy of epcoritamab plus lenalidomide compared to rituximab plus gemcitabine and oxaliplatin in treating relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). This study is significant as it explores new treatment options for this aggressive form of cancer, potentially improving patient outcomes.
The study involves three treatment arms: one receiving subcutaneous injections of epcoritamab plus oral lenalidomide, another receiving intravenous rituximab plus gemcitabine and oxaliplatin, and a third receiving only epcoritamab. The goal is to determine which treatment is most effective in managing DLBCL.
This randomized, open-label study follows a parallel intervention model with no masking. Its primary purpose is treatment, aiming to enroll around 360 participants across 165 global sites.
The study began on August 13, 2024, with an estimated completion date yet to be announced. The last update was submitted on August 4, 2025, indicating ongoing progress.
For investors, this study could impact AbbVie and Genmab’s stock performance, especially if the results show promising outcomes. The competitive landscape in oncology treatments is fierce, and successful trials can lead to significant market advantages.
The study is ongoing, with further details available on the ClinicalTrials portal.